TrialAnnals of oncology : official journal of the European Society for Medical Oncology2021

Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.

S Dent et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.